PHAT Phathom Pharmaceuticals

Phathom to Participate at the 19th Annual Needham Virtual Healthcare Conference

Phathom to Participate at the 19th Annual Needham Virtual Healthcare Conference

FLORHAM PARK, N.J., April 09, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that company management will participate in one-on-one meetings at the upcoming 19th Annual Needham Virtual Healthcare Conference from Tuesday, April 14, 2020 through Wednesday, April 15, 2020.

About Phathom

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the company’s website at and follow Phathom on LinkedIn at .

CONTACTS

Joe Hand

1-877-742-8466

Media Contact:

Nick Benedetto

1-877-742-8466

Investor Contact:

Patti Bank

Westwicke Partners

415-513-1284

EN
09/04/2020

Underlying

PHATPhathom Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Phathom Pharmaceuticals

 PRESS RELEASE
Free
PHAT Phathom Pharmac...

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Fi...

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026 Management to host conference call on Thursday, February 26, 2026, at 8:00 am EST FLORHAM PARK, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EST on Thursday, February 26, 2026, to report its fourth quarter and full year 2025 fina...

February 17, 2026 1 EN
 PRESS RELEASE
Free
PHAT Phathom Pharmac...

Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook ...

Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026 FLORHAM PARK, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team will participate in a fireside chat at the Guggenheim Emerging Outlook Biotech Summit 2026 on Thursday, February 12, 2026, at 11:30 am EST. Company management will also participate in one-on-one meetings during the conference, wh...

February 5, 2026 1 EN
 PRESS RELEASE
Free
PHAT Phathom Pharmac...

Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offer...

Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today the pricing of an underwritten public offering of 6,875,000 shares of its common stock and pre-funded warrants to purchase 1,250,078 shares of common stock. The shares of common stock are being sold to the public at a price of $16.00 per shar...

January 8, 2026 1 EN
 PRESS RELEASE
Free
PHAT Phathom Pharmac...

Phathom Pharmaceuticals Announces Proposed Public Offering of Common S...

Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, in an underwritten public offe...

January 7, 2026 1 EN
 PRESS RELEASE
Free
PHAT Phathom Pharmac...

Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full ...

Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced certain preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025.Preliminary Fourth Quarter 2025 Financial Results For the three months ended December 31, 2025, Phathom expects to report: Net revenues of approxima...

January 7, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch